Charles River Laboratories International, Inc. (NYSE:CRL) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Charles River has an average analyst rating of Moderate Buy from 16 brokers (11 buy, 4 hold, 1 sell) with a mean 12‑month price target of $205.36, though recent analyst targets vary widely (roughly $175–$265).
• The company slightly beat its latest quarter (EPS $2.39 vs $2.33 est.; revenue $994.2M vs $987M est.) but revenue was down 0.8% YoY and net margin remained negative (-3.59%); management set FY2026 guidance of 10.700–11.200 EPS, near the analyst consensus of 10.97.
• Shares trade around $165.92 with a market cap of $8.19B, a negative P/E (-56.05), a 52‑week range of $113.89–$228.88, and high institutional ownership (98.9%).

Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report) has received an average rating of "Moderate Buy" from the sixteen brokerages that are covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and eleven have given a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $205.3571.

Several brokerages have commented on CRL. Mizuho cut their price objective on Charles River Laboratories International from $215.00 to $175.00 and set a "neutral" rating on the stock in a research report on Friday, February 20th. Citigroup lifted their target price on Charles River Laboratories International from $200.00 to $265.00 and gave the stock a "buy" rating in a research report on Friday, January 16th. Robert W. Baird set a $193.00 target price on shares of Charles River Laboratories International in a research note on Thursday, February 19th. Evercore restated an "outperform" rating on shares of Charles River Laboratories International in a report on Wednesday, April 8th. Finally, Royal Bank Of Canada assumed coverage on shares of Charles River Laboratories International in a research note on Tuesday, April 14th. They issued an "outperform" rating and a $215.00 price target on the stock.

Charles River Laboratories International Stock Performance

Shares of NYSE:CRL opened at $165.92 on Friday. The stock has a market capitalization of $8.19 billion, a P/E ratio of -56.05, a PEG ratio of 2.00 and a beta of 1.45. Charles River Laboratories International has a 52 week low of $113.89 and a 52 week high of $228.88. The company has a quick ratio of 1.02, a current ratio of 1.29 and a debt-to-equity ratio of 0.67. The firm has a fifty day simple moving average of $169.78 and a two-hundred day simple moving average of $183.07.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last issued its quarterly earnings data on Wednesday, February 18th. The medical research company reported $2.39 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.33 by $0.06. Charles River Laboratories International had a positive return on equity of 15.60% and a negative net margin of 3.59%.The business had revenue of $994.23 million for the quarter, compared to the consensus estimate of $986.98 million. During the same period in the prior year, the business posted $2.66 earnings per share. The company's quarterly revenue was down .8% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. On average, analysts expect that Charles River Laboratories International will post 10.97 earnings per share for the current fiscal year.

Institutional Trading of Charles River Laboratories International

Institutional investors and hedge funds have recently modified their holdings of the stock. Tema Etfs LLC bought a new position in Charles River Laboratories International in the fourth quarter worth approximately $26,000. Rothschild Investment LLC increased its holdings in Charles River Laboratories International by 82.4% during the 3rd quarter. Rothschild Investment LLC now owns 186 shares of the medical research company's stock worth $29,000 after purchasing an additional 84 shares during the period. Atlantic Union Bankshares Corp bought a new stake in Charles River Laboratories International during the 3rd quarter valued at $31,000. Los Angeles Capital Management LLC purchased a new stake in shares of Charles River Laboratories International in the 4th quarter worth $42,000. Finally, Sfam LLC purchased a new stake in shares of Charles River Laboratories International in the 4th quarter worth $43,000. Institutional investors own 98.91% of the company's stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.